GLUCAGON-like peptide-1 agonistsTYPE 2 diabetesBLOOD sugarHYPOGLYCEMIC agentsGlucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing...
New-generation antidiabetic agents, particularly those targeting the glucagon-like peptide-1 (GLP-1) pathway, represent a significant advancement in the treatment of type 2 diabetes. GLP-1 is an incretin hormone that is secreted in response to food intake, and it exerts multiple actions conducive...
GLP-1 agonists are medications used to treat type 2 diabetes mellitus in adults. They are sometimes referred to as incretin mimetics, GLP-1 analogs, or GLP-1 receptor agonists. A few drugs in this class are exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. Insulin ...
New-generation antidiabetic agents, particularly those targeting the glucagon-like peptide-1 (GLP-1) pathway, represent a significant advancement in the treatment of type 2 diabetes. GLP-1 is an incretin hormone that is secreted in response to food intake, and it exerts multiple actions conducive...
Furthermore, Exendin-4 treatment significantly diminished the TBI-induced overexpression of TNF伪 and IL-1尾, as well as phosphorylation of p38 and ERK1/2. These data suggest a strong beneficial action of the glucagon-like peptide-1 receptor agonist Exendin-4 in improving neurological outcomes by...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment oftype 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel ...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
et al. Exendin-4, glucagon-like peptide-1 receptor agonist, enhances isoflurane-induced preconditioning against myocardial infarction via caveolin-3 expression. Eur. Rev. Med. Pharmacol. Sci. 19, 1285–1290 (2015). CAS PubMed Google Scholar Dong, Z. et al. Protein kinase A mediates glucagon...
15.Wu Z, Deng W, Ye Y, Xu J, Han D, Zheng Y, Zheng Q. Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes.Front Endocrinol (Lausanne). 2024;15:1378291.[PubMed][DOI][Cited in This Article:1][Refer...
The glucagon-like peptide 1 receptor agonist (GLP-1RA) class of pharmaceuticals are highly effective agents for the treatment of T2D and for achieving weight loss.4-9GLP-1RAs have further been shown to reduce the risk of adverse cardiovascular outcomes in patients with obesity10and to contribute...